查詢結果分析
相關文獻
- Significant Decrease in Serum IL-6 and MMP-3 after Etanercept Treatment in Ankylosing Spondylitis Patients
- Estimated Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Rheumatic Diseases Treated with Tumor Necrosis Factor Blockers
- Circulating Levels of Tumor Necrosis Factor Receptors I and II: Biomarkers for Ankylosing Spondylitis and Rheumatoid Arthritis
- Serum Levels of Interleukin 12p70 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
- The Expression of Proinflammatory Cytokines and Intracellular Minerals in Patients with Ankylosing Spondylitis
- Fas and CD45RO Antigen Expression on Peripheral Blood Mononuclear Cells in Patients with Ankylosing Spondylitis: A Comparison with Autoimmune Diseases
- 中藥對過敏性鼻炎治療之免疫機轉研究
- 急性躁期患者細胞免疫功能之活化
- 氣功外氣對人類早期單核細胞株和流行性感冒病毒的效應
- 僵直性脊椎炎病案二例
頁籤選單縮合
題 名 | Significant Decrease in Serum IL-6 and MMP-3 after Etanercept Treatment in Ankylosing Spondylitis Patients=僵直性脊椎炎的華人使用恩博治療後血清細胞白介素-6和基質金屬蛋白酶-3顯著降低 |
---|---|
作 者 | 蕭凱鴻; 蔡長祐; 張德明; 賴振宏; 魏正宗; 陳堃宏; 林世昌; 呂聆音; 周昌德; | 書刊名 | 中華民國風濕病雜誌 |
卷 期 | 25:1/2 2011.12[民100.12] |
頁 次 | 頁11-19 |
分類號 | 418.29 |
關鍵詞 | 恩博; 僵直性脊椎炎; 細胞激素; 細胞白介素-6; 基質金屬蛋白酶-3; Etanercept; Ankylosing spondylitis; Cytokines; IL-6; MMP-3; |
語 文 | 英文(English) |
中文摘要 | 目的:評估僵直性脊椎炎的華人使用恩博治療前後,血清中細胞激素和發炎相關物質的變化。方法:14位患有僵直性脊椎炎的華人接受12週的恩博治療(25毫克,一週兩次),於治療前後測量血清中的腫瘤壞死因子-α、細胞白介素-1、細胞白介素-6,細胞白介素-8、細胞白介素-10、轉化生長因子-β、腫瘤壞死因子相關細胞凋亡誘導配體(TRAIL)、和基質金屬蛋白酶(MMP)。週邊血液單核細胞上的類鐸受體-2(Toll-like receptor 2,TLR-2)和類鐸受體-4(TLR-4)用流式細胞儀染色。結果:經過3個月的恩博治療,病患血中的腫瘤壞死因子-α從一開始量不到,到明顯增加,但各個月的值沒有明顯統計差異。細胞白介素-6濃度在經過治療後明顯下降(14.2 ± 14.5 pg/mL vs.3M, 4.0 ± 2.8 pg/mL, p=0.001);同時,血清中的基質金屬蛋白酶-3在治療後也是明顯減少(42.2 ± 29.7 ng/mL vs. 3M, 28.6 ± 26.5 ng/mL, p=0.005)。細胞白介素-1和細胞白介素-8測量不到;細胞白介素-10、轉化生長因子-β、和腫瘤壞死因子相關細胞凋亡誘導配體的濃度沒甚麼變化;而週邊血液單核細胞上表現的類鐸受體-2和類鐸受體-4在經過治療後下降,但沒有明顯差異。結論:僵直性脊椎炎經過短期恩博治療後,血清中的細胞白介素-6和基質金屬蛋白酶-3會顯著下降。 |
英文摘要 | Objective: To evaluate the changes in the level of serum cytokines and inflammation-related mediators before and after etanercept treatment in patients with ankylosing spondylitis (AS).Methods: In an open-label 12-week trial of etanercept (25 mg twice per week) in ethnic Chinese patients with AS, 14 subjects received laboratory tests before and after etanercept. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), transforming growth factor-β (TGF-β), TNF-related apoptosis-inducing ligand (TRAIL) and matrix metalloproteinase (MMP) were measured by enzyme-linked immunosorbent assay (ELISA). Peripheral blood mononuclear cells (PBMC) were stained for toll-like receptor (TLR) 2 and 4, using flow cytometry. Results: Before and 3 months after etanercept treatment, the results showed TNF-α was not detectable at baseline, but significantly increased after etanercept treatment for 2 weeks; however, there was no significant change from month to month. IL-6 in the serum was not very high at baseline, but it was significantly reduced after etanercept treatment (baseline, 14.2 ± 14.5 pg/mL vs. 3 months 4.0 ± 2.8 pg/mL, p=0.001). Like IL-6, MMP-3 also decreased significantly after etanercept treatment (baseline 42.2 ±29.7 ng/mL vs. 3 months 28.6 ± 26.5 ng/mL, p=0.005). IL-1 and IL-8 were not detected. IL-10, TGF-β, and TRAIL levels showed no change. The expression of TLR-2 and TLR-4 on PBMC decreased after 12 weeks, but this was not significant. Conclusion: Serum levels of IL-6 and MMP-3 were significantly decreased after short-term etanercept therapy. |
本系統中英文摘要資訊取自各篇刊載內容。